| Primary |
| Prophylaxis |
21.4% |
| Antifungal Prophylaxis |
12.7% |
| Fungal Infection |
11.9% |
| Acute Lymphocytic Leukaemia |
5.4% |
| Drug Use For Unknown Indication |
5.2% |
| Acute Myeloid Leukaemia |
4.4% |
| Pyrexia |
4.4% |
| Infection Prophylaxis |
4.0% |
| Product Used For Unknown Indication |
3.8% |
| Leukaemia |
3.6% |
| Nausea |
3.4% |
| Hypertension |
3.2% |
| Prophylaxis Of Nausea And Vomiting |
3.2% |
| Aspergillosis |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Abdominal Pain |
1.8% |
| Zygomycosis |
1.8% |
| Bronchopulmonary Aspergillosis |
1.6% |
| Diabetes Mellitus |
1.6% |
| Pneumonia Fungal |
1.6% |
|
| Vomiting |
11.3% |
| Respiratory Failure |
9.3% |
| Death |
8.2% |
| Pyrexia |
7.2% |
| Zygomycosis |
7.2% |
| Renal Failure |
6.2% |
| Stem Cell Transplant |
5.2% |
| Cardiac Failure |
4.1% |
| Hepatic Enzyme Increased |
4.1% |
| Septic Shock |
4.1% |
| Thrombocytopenia |
4.1% |
| Transaminases Increased |
4.1% |
| Drug Ineffective |
3.1% |
| Drug Interaction |
3.1% |
| Liver Disorder |
3.1% |
| No Therapeutic Response |
3.1% |
| Puncture Site Infection |
3.1% |
| Squamous Cell Carcinoma Of Skin |
3.1% |
| Systemic Candida |
3.1% |
| Thrombotic Thrombocytopenic Purpura |
3.1% |
|
| Secondary |
| Prophylaxis |
15.5% |
| Acute Myeloid Leukaemia |
12.8% |
| Product Used For Unknown Indication |
10.4% |
| Infection Prophylaxis |
7.4% |
| Antifungal Prophylaxis |
6.8% |
| Pyrexia |
4.7% |
| Prophylaxis Of Nausea And Vomiting |
4.3% |
| Hypertension |
4.2% |
| Drug Use For Unknown Indication |
3.9% |
| Fungal Infection |
3.8% |
| Bronchopulmonary Aspergillosis |
3.4% |
| Aspergillosis |
3.3% |
| Abdominal Pain |
3.2% |
| Systemic Mycosis |
2.8% |
| Zygomycosis |
2.8% |
| Nausea |
2.6% |
| Depression |
2.1% |
| Immunosuppression |
2.1% |
| T-cell Lymphoma |
2.0% |
| Infection |
1.9% |
|
| Vomiting |
9.8% |
| Renal Failure |
8.7% |
| Sepsis |
8.7% |
| Neutrophil Pelger-huet Anomaly Present |
7.6% |
| Cytolytic Hepatitis |
5.4% |
| Hyperbilirubinaemia |
5.4% |
| Septic Shock |
5.4% |
| Weight Decreased |
5.4% |
| Drug Ineffective |
4.3% |
| Sinoatrial Block |
4.3% |
| Vaginal Discharge |
4.3% |
| Zygomycosis |
4.3% |
| Blood Alkaline Phosphatase Increased |
3.3% |
| Drug Interaction |
3.3% |
| Febrile Neutropenia |
3.3% |
| Long Qt Syndrome |
3.3% |
| Malabsorption |
3.3% |
| Neutropenia |
3.3% |
| Organising Pneumonia |
3.3% |
| Pyrexia |
3.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.5% |
| Acute Myeloid Leukaemia |
14.4% |
| Prophylaxis |
13.4% |
| Drug Use For Unknown Indication |
13.3% |
| Acute Lymphocytic Leukaemia |
4.1% |
| Nausea |
3.7% |
| Pain |
3.5% |
| Antifungal Prophylaxis |
2.7% |
| Infection Prophylaxis |
2.4% |
| Pyrexia |
2.4% |
| Sedation |
2.2% |
| Stem Cell Transplant |
2.0% |
| Hypertension |
1.8% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Graft Versus Host Disease |
1.5% |
| Chronic Lymphocytic Leukaemia Refractory |
1.4% |
| Hiv Infection |
1.3% |
| Fungal Infection |
1.2% |
| Antiviral Prophylaxis |
1.2% |
| Prophylaxis Against Graft Versus Host Disease |
1.2% |
|
| Sepsis |
16.3% |
| Pneumonia |
8.7% |
| Febrile Neutropenia |
8.2% |
| Thrombocytopenia |
8.2% |
| White Blood Cell Count Decreased |
6.0% |
| Zygomycosis |
6.0% |
| Septic Shock |
4.9% |
| Drug Ineffective |
4.3% |
| Pyrexia |
4.3% |
| Renal Failure Acute |
4.3% |
| Neuropathy Peripheral |
3.8% |
| Rhabdomyolysis |
3.3% |
| Viral Haemorrhagic Cystitis |
3.3% |
| Graft Versus Host Disease |
2.7% |
| Nephropathy Toxic |
2.7% |
| Neutropenia |
2.7% |
| Renal Failure |
2.7% |
| Staphylococcal Bacteraemia |
2.7% |
| Vomiting |
2.7% |
| Acute Pulmonary Oedema |
2.2% |
|
| Interacting |
| Antifungal Prophylaxis |
17.5% |
| Prophylaxis Against Graft Versus Host Disease |
10.2% |
| Acute Promyelocytic Leukaemia |
8.5% |
| Pyrexia |
8.5% |
| Graft Versus Host Disease |
7.9% |
| Prophylaxis |
7.3% |
| Febrile Neutropenia |
6.8% |
| Zygomycosis |
4.5% |
| Acute Lymphocytic Leukaemia |
3.4% |
| Fungal Infection |
3.4% |
| Product Used For Unknown Indication |
3.4% |
| Epilepsy |
2.3% |
| Fluid Replacement |
2.3% |
| Gastritis Prophylaxis |
2.3% |
| Nausea |
2.3% |
| Stomatitis |
2.3% |
| Supportive Care |
2.3% |
| Antifungal Treatment |
1.7% |
| Antiviral Prophylaxis |
1.7% |
| Convulsion Prophylaxis |
1.7% |
|
| Drug Interaction |
20.5% |
| Multi-organ Failure |
12.8% |
| Vomiting |
12.8% |
| Febrile Neutropenia |
10.3% |
| Abdominal Distension |
5.1% |
| Blood Bilirubin Increased |
2.6% |
| Diarrhoea |
2.6% |
| Encephalopathy |
2.6% |
| Hepatotoxicity |
2.6% |
| Immunosuppressant Drug Level Increased |
2.6% |
| Metabolic Acidosis |
2.6% |
| Mucormycosis |
2.6% |
| Myositis |
2.6% |
| Neuropathy Peripheral |
2.6% |
| Pneumonitis |
2.6% |
| Septic Shock |
2.6% |
| Sinoatrial Block |
2.6% |
| Thrombocytopenia |
2.6% |
| Thrombotic Thrombocytopenic Purpura |
2.6% |
| Torsade De Pointes |
2.6% |
|
